nopparit/iStock via Getty Images
- Keros Therapeutics (NASDAQ:KROS) traded higher on Tuesday after announcing that it has closed screening in its Phase 2 TROPOS trial for its lung disorder therapy cibotercept (KER-012).
- The global placebo-controlled trial is designed to evaluate cibotercept with background therapy for pulmonary arterial hypertension (PAH), a disease area served by United Therapeutics (UTHR), Johnson & Johnson (JNJ), and Merck (MRK).
- With screening for TROPOS closed, Keros (KROS) said it plans to complete enrollments by the end of September. The company is eyeing a topline data readout in Q2 2025, which, according to its CEO Jasbir Seehra, indicates an accelerated timeline.
- “The tremendous demand and speed we have observed in enrolling this trial will enable us to present topline data earlier than anticipated, now expected in the second quarter of 2025,” Seehra said.
